• If you are wondering whether Edwards Lifesciences at around US$83.20 still offers value, the key question is how its current price stacks up against what the business may be worth.
• The stock has returned 2.4% over the past week and 2.5% over the past month, with a 10.9% return over the last year but a year to date return of 2.5% decline and softer 3 year and 5 year returns of 6.4% and 4.9% declines.
• Recent headlines around Edwards Lifesciences have focused on its role in the broader medical devices space and how investors are weighing long term demand for cardiovascular treatments against changing expectations for growth and risk. This backdrop helps explain why the stock's shorter term gains sit alongside more mixed performance over longer periods.
• According to Simply Wall St's valuation checks, Edwards Lifesciences currently scores 1 out of 6 for being undervalued. Next, it is worth walking through the different valuation approaches used, and then looking at a more complete way to think about value that ties everything together at the end of this article.

Edwards Lifesciences scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Edwards Lifesciences Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s dollars, aiming to estimate what the whole business might be worth right now.

For Edwards Lifesciences, the model used is a 2 Stage Free Cash Flow to Equity approach, based on recent free cash flow of about $1.30b. Analysts provide explicit forecasts out to 2028, with Simply Wall St extrapolating further to build a 10 year path of cash flows, including projected free cash flow of $2.94b in 2035.

Those projected cash flows are discounted back to today and combined with an estimate of value beyond the 10 year window. This produces an intrinsic value estimate of about $88.76 per share, compared with a current share price of around $83.20.

The implied 6.3% discount suggests the stock is trading close to this DCF estimate rather than at a deep discount or premium.

Result: ABOUT RIGHT

Edwards Lifesciences is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Edwards Lifesciences Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much you are paying for each dollar of current earnings. Investors usually accept a higher P/E when they expect stronger growth or see the earnings as relatively predictable and lower risk, and a lower P/E when growth expectations or perceived risks are more muted.

Edwards Lifesciences currently trades on a P/E of about 44.6x. That sits well above the Medical Equipment industry average of about 23.6x and above a peer group average of around 25.0x, which suggests the stock is priced more richly than many sector peers on this measure.

Simply Wall St’s Fair Ratio for Edwards Lifesciences is 28.8x. This is a proprietary estimate of what the P/E might be given the company’s earnings profile, industry, profit margins, market cap and a range of risk factors. Because it adjusts for these company specific drivers, it can be more informative than a simple comparison with peers or the broad industry.

Comparing the Fair Ratio of 28.8x with the current P/E of 44.6x points to the stock trading above this blended benchmark.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Edwards Lifesciences Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are worth introducing as a simple story you build around Edwards Lifesciences that links your view of its products, opportunities and risks to a set of revenue, earnings and margin forecasts. These then connect to a Fair Value that you can compare with the current share price on Simply Wall St’s Community page. Narratives are kept up to date as new news or earnings arrive. For Edwards Lifesciences, one investor might focus on product launches like TAVR, EVOQUE and Sapien M3 and lean toward the higher analyst target of US$110. Another might focus on tariffs, competitive pressure and acquisition related EPS dilution and sit closer to the lower target of US$84, using those different stories and Fair Values to help decide whether the current price looks attractive or stretched.

Do you think there's more to the story for Edwards Lifesciences? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.